Q-omics provides the consensus-scored FOXP4 profile across patient tissues and cancer cell-line models. FOXP4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FOXP4 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, FOXP4 RNA expression shows 19,849 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where FOXP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXP4 survival associations across molecular data types. FOXP4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXP4 RNA expression–survival associations across cancer types. High FOXP4 expression shows unfavorable associations in KIRC, MESO, LIHC and ACC, but favorable associations in PAAD and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FOXP4 RNA expression.
This table summarizes FOXP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXP4 shows lower tumor expression in KIRC and higher tumor expression in COAD, LIHC, STAD, HNSC and BRCA. The COAD box plot shows higher FOXP4 RNA expression in tumor versus normal tissue (log2 FC = +1.485, t-test p < 0.001).
This table shows molecular features associated with FOXP4 in patient tissues and cancer cell lines. In patient samples, FOXP4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
